SKYSCRAPER-07NCT04543617
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 54 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Primary completion date changed from estimate of Mar 31, 2027 to Jul 22, 2026
- Study sites: 167 to 166
- Minor Study sites: 165 to 167v52
- Minor Study sites revised (165)v51
- Minor Study sites: 166 to 165v50
- Minor Study sites revised (166)v49
Show 41 earlier versionsHide 41 earlier versions
- Minor Study sites: 163 to 166v48
- Minor Study sites: 179 to 163v47
- Minor Study sites: 180 to 179v46
- Minor Study sites: 181 to 180v44
- Minor Study sites: 185 to 181v42
- Minor Study sites: 190 to 185v41
- Minor Study sites: 193 to 190v40
- Notable Primary and study completion dates pushed to Mar 31, 2027
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 750 to confirmed 760
- Study sites: 231 to 193
- Minor Site details revised at 29 of 231 sitesv38
- Minor Site details revised at 27 of 231 sitesv37
- Minor Study sites revised (231)v36
- Minor Site details revised at 9 of 231 sitesv35
- Minor Site details revised at 12 of 231 sitesv34
- Minor Site details revised at 10 of 231 sitesv33
- Minor Site details revised at 14 of 231 sitesv32
- Minor Study sites revised (231)v31
- Minor Study sites revised (231)v30
- Minor Study completion date: Dec 26, 2025 to Jun 27, 2025
- Study sites revised (231)
- Minor Site details revised at 16 of 231 sitesv28
- Minor Study sites: 230 to 231v27
- Minor Study sites: 229 to 230v26
- Minor Study sites: 228 to 229v25
- Minor Study sites: 224 to 228v24
- Minor Study sites: 223 to 224v23
- Minor Site details revised at 14 of 223 sitesv22
- Minor Study sites: 220 to 223v21
- Minor Site details revised at 8 of 220 sitesv20
- Minor Study sites: 218 to 220v19
- Minor Study sites: 208 to 218v18
- Minor Study sites: 206 to 208v17
- Minor Study sites: 220 to 206v16
- Minor Study sites: 218 to 220v15
- Notable Eligibility criteria expanded, about 2 words
- Study sites: 215 to 218
- Minor Study sites: 214 to 215v12
- Minor Site details revised at 13 of 214 sitesv11
- Minor Study sites: 213 to 214v10
- Minor Study sites: 211 to 213v9
- Minor Study sites: 213 to 211v8
- Minor Study sites: 212 to 213v7
- Minor Study sites revised (212)v6
- Minor Study sites: 213 to 212v5
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (15)
Show 10 moreShow less
Arms and interventions
Participants will receive atezolizumab followed by tiragolumab.
Participants will receive atezolizumab followed by tiragolumab matching placebo.
Participants will receive matching placebos to tiragolumab and atezolizumab.
Drugs: Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo
Sites
166 sites in 28 countries
China 35, Japan 15, France 10, Spain 9, Russia 8, Germany 7, South Korea 7, Turkey (Türkiye) 7, Poland 6, Taiwan 6, United Kingdom 6, Austria 4, Italy 4, Thailand 4, Ukraine 4, Argentina 3, Australia 3, Belgium 3, Greece 3, Israel 3, Morocco 3, Portugal 3, South Africa 3, United States 3, Hungary 2, Kenya 2, Switzerland 2, New Zealand 1